Awakn Via Amitis

Awakn Life Sciences is a clinical-stage biotechnology company focused on developing and delivering psychedelic-assisted therapeutics to treat addiction and other mental health disorders. The company operates through two main pillars: a research and development division focused on clinical trials for substances like ketamine and MDMA, and a healthcare services division that operates specialized clinics. Their lead program, AWKN-001, is a Phase 3 trial investigating ketamine-assisted therapy for severe alcohol use disorder. Awakn aims to integrate pharmacological treatments with structured psychotherapy to provide more effective long-term outcomes for patients suffering from treatment-resistant conditions.